v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
General and administrative $ 1,136,709 $ 375,738
Research and development 109,434 9,259
Total operating expenses 1,246,143 384,997
Loss from operations (1,246,143) (384,997)
Other income:    
Net gain from change in fair value of derivative liability instrument 697,561
Amortization of deferred offering cost (477,647)
Interest income 49,679 5,165
Other income 5,578 51,285
Total other income 275,171 56,450
NET LOSS $ (970,972) $ (328,547)
Basic net loss per common share $ (0.03) $ (0.01)
Diluted net loss per common share $ (0.03) $ (0.01)
Weighted-average common shares outstanding, basic 29,476,002 26,956,217
Weighted-average common shares outstanding, diluted 29,476,002 26,956,217